3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
176
Colorectal Neoplasms
153
Rectal Neoplasms
122
Stomach Neoplasms
112
Pancreatic Neoplasms
60
Neoplasm Metastasis
60
Colonic Neoplasms
42
Triple Negative Breast Neoplasms
34
Neoplasms
29
Esophageal Neoplasms
28
Cholangiocarcinoma
17
Biliary Tract Neoplasms
17
Nasopharyngeal Carcinoma
16
Gallbladder Neoplasms
16
Carcinoma, Hepatocellular
16
Adenocarcinoma
16
Locally Advanced Rectal Cancer
15
Squamous Cell Carcinoma of Head and Neck
10
Head and Neck Neoplasms
10
Esophageal Squamous Cell Carcinoma
10
Brain Neoplasms
10
Bile Duct Neoplasms
10
Adenocarcinoma Of Esophagus
10
Liver Neoplasms
9
Gastrointestinal Neoplasms
9
Breast Neoplasms, Male
9
Neuroendocrine Tumors
7
Colorectal Cancer Metastatic
7
Carcinoma, Renal Cell
7
Ovarian Neoplasms
6
Interventions
durvalumab
5
Nivolumab
3
Cyclophosphamide
3
Cisplatin
3
130-nm albumin-bound paclitaxel
3
padeliporfin
2
anlotinib
2
Trabectedin
2
Sunitinib
2
Pemetrexed
2
Docetaxel
2
Chemoradiotherapy
2
Carboplatin
2
Bevacizumab
2
sotorasib
1
relatlimab
1
relacorilant
1
pembrolizumab
1
patritumab
1
palbociclib
1
olaparib
1
niraparib
1
nintedanib
1
montanide ISA 51
1
golotimod
1
genexol-PM
1
ceralasertib
1
cemiplimab
1
camrelizumab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms by Site
×
Capecitabine
×
Clear all
NCT04080843
2022-07-13
ALTER-C-002
Zhejiang University
Phase 2
Completed
30 enrolled